The HI-PEITHO trial results demonstrated that the EKOS system combined with anticoagulation is superior to anticoagulation alone for treating acute pulmonary embolism. The study showed a statistically significant reduction in clinical event rates among intermediate-risk patients. Findings were published in The New England Journal of Medicine and presented at the ACC.26 conference.
Boston Scientific (BSX) has released positive data from its CHAMPION-AF clinical trial regarding the Watchman FLX device. The study demonstrated that the device is as effective as oral anticoagulants in reducing stroke and death risks for patients with atrial fibrillation. Notably, the trial showed a significant…
Read the full storyEdwards Lifesciences (EW) announced successful 2-year follow-up data from its TRISCEND II clinical trial, bolstering confidence in its medical technologies. The data, presented at the ACC.26 conference, highlights the efficacy of the EVOQUE transcatheter tricuspid valve replacement (TTVR) system in improving patient…
Amgen (NASDAQ: AMGN) announced positive results from its VESALIUS-CV clinical trial, demonstrating that its drug Repatha significantly reduces cardiovascular risks. The study found that Repatha (evolocumab) lowered the risk of major adverse cardiovascular events (MACE) by 31% in high-risk primary prevention patients.…